Uncertainty Plagues ICER Report on Type 2 Diabetes

Just one thing stands between some Type 2 diabetes patients and disease management: a dislike of needles.  A new pill form of semaglutide, a medicine that aids in digestion and blood sugar regulation, could make treatment more feasible for these patients – improving lives and lowering overall health care costs.

But the Institute for Clinical and Economic Review has other ideas.

The controversial Boston-based health economics organization released a new evidence report that deems oral semaglutide not cost effective.  Perhaps that’s because ICER omits or undervalues several key factors in its calculation.  

Read more.